AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01643941 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
Study NCT01643941 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw
Description: Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
Study NCT01643941 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonization swab samples
Description: Colonization swabs will be collected from all subjects at various timepoints.
Study NCT01547520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: intramuscular, 25 mg, 5 to 10 minutes before EGD
Study NCT01547520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
Study NCT04394520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Introduction
Description: A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.
Study NCT04394520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Opt-in
Description: A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-in to the survey, if they do not respond, the survey will terminate.
Study NCT04394520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Opt-out
Description: A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-out to the survey, if they do not respond, the survey will continue.
Study NCT04394520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Opt-in
Description: A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to passively opt-in to the survey, if they do not hang-up, the survey will continue.
Study NCT03431051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Beverage Initiative
Description: A Healthy Beverage Initiative will be instituted at two hospital campuses.
Study NCT01176604 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given via catheter
Study NCT02814474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Na-3-hydroxybutyrate
Description: Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
Study NCT02814474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of 0.9 % saline
Study NCT01045122 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
Study NCT01045122 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
Study NCT00997724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a-VATS
Description: In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
Study NCT01526811 — intervention group
Intervention type: DEVICE
Intervention: Endurant Stent graft
Description: Endurant Stent graft implantation
Study NCT03678259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124I-p5+14 Injection
Description: 124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge
Study NCT03710213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message-based Intervention
Description: The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
Study NCT00468442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Pancreatic Islet Cells
Description: transplant of islet cells injected into the portal vein of the liver
Study NCT00468442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
Study NCT02280057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1500 mg (=2 pills) per day in six months
Study NCT02280057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 pills per day in six months; pills look like metformin pills
Study NCT03239873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX® PE34 Process
Description: Varicella virus vaccine live manufactured with a new passage extension process (PE34)
Study NCT03239873 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX® 2016 Commercial Process
Description: Varicella virus vaccine live manufactured with the 2016 commercial process
Study NCT03239873 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II®
Description: Measles, Mumps, and Rubella virus vaccine live
Study NCT03239873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II®
Description: Measles, Mumps, and Rubella virus vaccine live
Study NCT01365533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Roflumilast 500 μg, one tablet once daily, orally
Study NCT01365533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one tablet once daily, orally
Study NCT00468442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Will replace antithymocyte globulin in all islet transplantations after the first one
Study NCT00468442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Depletes transient B-cells
Study NCT03369184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: The intervention is administered as previously described. The duration of intervention is 10 minutes.
Study NCT03369184 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ambient air
Description: Administered similarly to treatment arm, via an open face mask and during 10 minutes
Study NCT02760758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI
Study NCT00468442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Maintenance immunosuppressive therapy
Study NCT03761758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle lenses
Description: Spectacle lenses with clear central apertures
Study NCT02760758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients
Study NCT01054300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 2 mg single dose
Description: Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose
Study NCT01054300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 2 mg split into twice daily
Description: Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
Study NCT01054300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 4 mg single dose
Description: Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose
Study NCT01054300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 4 mg split into twice daily
Description: Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day
Study NCT01054300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to ertugliflozin administered as a single dose
Study NCT01614782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5823
Description: MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.
Study NCT01715337 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pulmonary rehabilitation
Description: 3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
Study NCT01614782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
Study NCT03324516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-Suspension of the temporal muscle after a craniotomy.
Description: The temporal muscle cuff will be used to re-suspend the temporal muscle after a traditional craniotomy.
Study NCT03324516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional re-suspension of the temporal muscle
Description: The temporal muscle will be re-suspended to the bone plate that is used to fixate the temporal bone that is removed for the craniotomy.
Study NCT02100670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% diclofenac sodium plus 3% menthol
Description: To be applied four times daily for 10 days.
Study NCT02100670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% diclofenac sodium plus 0.09% menthol
Description: To be applied four times daily for 10 days.
Study NCT02100670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% menthol
Description: To be applied four times daily for 10 days.
Study NCT02100670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with 0.09% menthol gel
Description: To be applied four times daily for 10 days.
Study NCT02047994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy
Description: Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~* Esomeprazole 40 mg bid for 10 days~* Clarithromycin 500 mg bid for 10 days~* Amoxicillin 1000 mg bid for 10 days
Study NCT00536549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian RT
Study NCT00536549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education about the self monitoring blood glucose
Study NCT00811317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop
Description: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target
Study NCT01282164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucagon stimulation test and insulin tolerance test
Description: glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
Study NCT01282164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucagon stimulation test and insulin tolerance test
Description: glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
Study NCT03339726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation Phenylephrine HCl
Description: 2 doses of one tablet 12 hours apart
Study NCT03339726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Phenylephrine HCl
Description: 4 doses of one capsule 4 hours apart
Study NCT03339726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 doses of placebo capsule and tablet taken 4 hours apart
Study NCT02530411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
Study NCT02530411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
Study NCT02530411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
Study NCT01103453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Action Planning Supermarket (VAP-S) Software
Description: The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.~We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention.
Study NCT03808324 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic investigations
Description: Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.
Study NCT02339116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoruracil
Study NCT02339116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoruracil
Study NCT02339116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT02339116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT02339116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02339116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT02339116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02348398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 600 mg by mouth daily in a 28 day cycle.
Study NCT02348398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.25 mg by mouth daily for 21 days of a 28 day cycle.
Study NCT02348398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
Study NCT02339116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT03852368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The effects of exercise with different intensity on the executive functions of adolescents
Study NCT03316417 — intervention group
Intervention type: OTHER
Intervention: Renal Tolerance to Immunotherapy
Description: The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.
Study NCT00674323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin Photodynamic Therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.
Study NCT00674323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin Photodynamic Therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.
Study NCT00674323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
Study NCT00674323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
Study NCT03609125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBS eyedrop
Description: The product is dispensed as sterile frozen vials containing 0.8 ml of product for the daily administration. The product is thawed and administered at a dose of 1 drop / 8 times each eye during the waking period.
Study NCT04806230 — intervention group
Intervention type: DRUG
Intervention: sertraline, mirtazapine, venlafaxine, citalopram, escitalopram
Description: Naturalistic treatment
Study NCT03623932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: immunosuppressor/TNFalpha
Description: Standard Treatment : immunosuppressor/TNFalpha as in standard practice
Study NCT03623932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: 8 hypnosis group sessions during 2 months
Study NCT01200537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: This group of patients will receive estradiol patches prior to the IVF cycle.
Study NCT01200537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Description: This group of patients will receive OCP's prior to the IVF cycle.
Study NCT03535402 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sarilumab
Description: SC administration of 200 mg twice a week
Study NCT02144948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: e.-coli-nissle
Description: 1 ml qd for 24 weeks
Study NCT00172081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Daily subcutaneous injection with placebo
Study NCT00172081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11
Description: PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
Study NCT03804190 — intervention group
Intervention type: OTHER
Intervention: questionaire
Description: dutch musculoskeletal questionaire
Study NCT04394507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Near-Infrared Fluorescence imaging
Description: .Near-infrared imaging was used to evaluate the function of the superficial lymphatic vessels in the right lower leg and foot as previously described.doi: 10.1161/CIRCIMAGING.118.008074.
Study NCT04394507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Strain Gauge Plethysmography
Description: Strain Gauge Plethysmography to asses capillary filtration rate og the lower limb
Study NCT02803567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief psycho-educational intervention
Description: Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
Study NCT01446263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial access versus femoral access for coronary angiography and intervention
Description: Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts